Literature DB >> 28097236

Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.

Margaret F Bennewitz1, Maritza A Jimenez1,2, Ravi Vats1,2, Egemen Tutuncuoglu1, Jude Jonassaint1,3, Gregory J Kato1,3, Mark T Gladwin1,4, Prithu Sundd1,2,4.   

Abstract

In patients with sickle cell disease (SCD), the polymerization of intraerythrocytic hemoglobin S promotes downstream vaso-occlusive events in the microvasculature. While vaso-occlusion is known to occur in the lung, often in the context of systemic vaso-occlusive crisis and the acute chest syndrome, the pathophysiological mechanisms that incite lung injury are unknown. We used intravital microscopy of the lung in transgenic humanized SCD mice to monitor acute vaso-occlusive events following an acute dose of systemic lipopolysaccharide sufficient to trigger events in SCD but not control mice. We observed cellular microembolism of precapillary pulmonary arteriolar bottlenecks by neutrophil-platelet aggregates. Blood from SCD patients was next studied under flow in an in vitro microfluidic system. Similar to the pulmonary circulation, circulating platelets nucleated around arrested neutrophils, translating to a greater number and duration of neutrophil-platelet interactions compared with normal human blood. Inhibition of platelet P-selectin with function-blocking antibody attenuated the neutrophil-platelet interactions in SCD patient blood in vitro and resolved pulmonary arteriole microembolism in SCD mice in vivo. These results establish the relevance of neutrophil-platelet aggregate formation in lung arterioles in promoting lung vaso-occlusion in SCD and highlight the therapeutic potential of targeting platelet adhesion molecules to prevent acute chest syndrome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28097236      PMCID: PMC5214368          DOI: 10.1172/jci.insight.89761

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  47 in total

Review 1.  Mechanisms of leukocyte sequestration in inflamed lungs.

Authors:  C M Doerschuk
Journal:  Microcirculation       Date:  2001-04       Impact factor: 2.628

2.  Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice.

Authors:  J David Holtzclaw; Daniel Jack; Samuel M Aguayo; James R Eckman; Jesse Roman; Lewis L Hsu
Journal:  Am J Respir Crit Care Med       Date:  2003-12-18       Impact factor: 21.405

3.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

4.  Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: comment on Jennings, et al British Journal of Haematology, 2014, 167:600-607.

Authors:  Michael Nagler; Walter A Wuillemin
Journal:  Br J Haematol       Date:  2014-11-19       Impact factor: 6.998

5.  Antibodies against neutrophil LY6G do not inhibit leukocyte recruitment in mice in vivo.

Authors:  Bryan G Yipp; Paul Kubes
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

6.  Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.

Authors:  Grace Chen; Dachuan Zhang; Tobias A Fuchs; Deepa Manwani; Denisa D Wagner; Paul S Frenette
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 7.  A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth I Ataga; Lillian McMahon; Joanna Howard; Frederic Galacteros; Ward Hagar; Elliott Vichinsky; Anthony T W Cheung; Neil Matsui; Stephen H Embury
Journal:  Am J Hematol       Date:  2012-04-10       Impact factor: 10.047

8.  Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection.

Authors:  Graciela Andonegui; Hong Zhou; Daniel Bullard; Margaret M Kelly; Sarah C Mullaly; Braedon McDonald; Elizabeth M Long; Stephen M Robbins; Paul Kubes
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Platelet activation and inhibition in sickle cell disease (pains) study.

Authors:  Andrew L Frelinger; Joseph A Jakubowski; Julie K Brooks; Sabrina L Carmichael; Michelle A Berny-Lang; Marc R Barnard; Matthew M Heeney; Alan D Michelson
Journal:  Platelets       Date:  2013-03-07       Impact factor: 3.862

10.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

View more
  52 in total

Review 1.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 2.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

3.  Quantifying Shear-Induced Deformation and Detachment of Individual Adherent Sickle Red Blood Cells.

Authors:  Yixiang Deng; Dimitrios P Papageorgiou; Hung-Yu Chang; Sabia Z Abidi; Xuejin Li; Ming Dao; George Em Karniadakis
Journal:  Biophys J       Date:  2018-12-18       Impact factor: 4.033

4.  Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.

Authors:  Carl Amilon; Mohammad Niazi; Anders Berggren; Magnus Åstrand; Bengt Hamrén
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

5.  Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease.

Authors:  Jing Li; Si-Yeon Jeong; Bei Xiong; Alan Tseng; Andrew B Mahon; Steven Isaacman; Victor R Gordeuk; Jaehyung Cho
Journal:  Haematologica       Date:  2019-10-31       Impact factor: 9.941

6.  Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.

Authors:  Yunfeng Liu; Hui Zhong; Weili Bao; Avital Mendelson; Xiuli An; Patricia Shi; Stella T Chou; Deepa Manwani; Karina Yazdanbakhsh
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

7.  Combination Therapy Targeting Platelet Activation and Virus Replication Protects Mice against Lethal Influenza Pneumonia.

Authors:  Sivasami Pulavendran; Jennifer M Rudd; Prasanthi Maram; Paul G Thomas; Ramachandran Akhilesh; Jerry R Malayer; Vincent T K Chow; Narasaraju Teluguakula
Journal:  Am J Respir Cell Mol Biol       Date:  2019-12       Impact factor: 6.914

8.  Neutrophils develop rapid proinflammatory response after engulfing Hb-activated platelets under intravascular hemolysis.

Authors:  A Bhasym; G K Annarapu; S Saha; N Shrimali; S Gupta; T Seth; P Guchhait
Journal:  Clin Exp Immunol       Date:  2019-05-27       Impact factor: 4.330

9.  Platelets at the crossroads of thrombosis, inflammation and haemolysis.

Authors:  Sebastian Vogel; Swee Lay Thein
Journal:  Br J Haematol       Date:  2018-01-30       Impact factor: 6.998

10.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.